Project Description:
Title: MOUNTAINSIDE (0367-CL-1201): A randomized, double-blind, placebo-controlled adaptive phase 2/3 Study with open-label extension to assess the efficacy, safety and tolerability of ASP0367 in participants with primary mitochondrial myopathy
Role: Site PI
Funding: Astellas Pharma Inc.
October 2021-present
Summary: This is a randomized, double-blind, placebo-controlled, oral dose, adaptive phase 2/3 study with open-label extension to evaluate the efficacy, safety and tolerability of ASP0367 in participants with primary mitochondrial myopathy.